Skip to content Skip to footer
Viewpoints_Raphaël Ortiz

Enhancing Diagnostic Capabilities in Prostate Cancer: Raphaël Ortiz from Telix Pharmaceuticals in a Riveting Conversation with PharmaShots

Shots:  Telix Pharmaceuticals’ Illuccix is approved in the UK for detecting and localizing prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET imaging.  Amidst a shortage of PET imaging agents in the UK and mainland Europe, Telix Pharmaceuticals has secured a significant advantage through an exclusive distribution partnership with Xiel Limited  Raphaël…

Read more

Viewpoints_Ahsan Arozullah

Astellas at ASCO 2024: Ahsan Arozullah in an Illuminating Dialogue Exchange with PharmaShots

Shots:  At ASCO 2024, Astellas Pharma presented 16 abstracts across several types of cancers with unmet medical needs  Today at PharmaShots, we have Ahsan Arozullah Sr. VP, Head of Oncology Development, shedding light on the advancement Astellas’ oncology portfolio for urothelial carcinoma, gastric cancer, and prostate cancer  Ahsan talks about the presented results from studies…

Read more

Spotlight Interview_David Esposito

Spotlight Interview: David Esposito CEO at ONL Therapeutics in a Stimulating Conversation with PharmaShots

“Spotlight-Company of the Month” offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people.  This month at PharmaShots’ Spotlight, we had an opportunity to engage in conversation with David Esposito CEO at ONL Therapeutics.  David discusses the company's lead candidate ONL1204, which is…

Read more

Exclusive Interview_Shmulik Shapiro

Shmulik Shapiro, EVP of Business Development & Strategy at RSIP Vision Shares Insight on New AI Tool for Prostate MRI Analysis that Supports PI-RADS Scoring

Shots: Shmulik spoke about the key features and development of the new AI tool for Prostate MRI Analysis Shmulik emphasized the significance of this new tool in PI-RADS score and how this can be helpful in diagnosing prostate lesions in MRI The interview provides a deeper understanding of medical imaging technologies that are emerging through…

Read more

PharmaShots Interview Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine

PharmaShots Interview: Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine

In an interview with PharmaShots, Todd Cohen, MD, Vice President of Medical Affairs/Medical Director of Urology at Myriad Genetics shares his views on the precision medicine and prognostic tests for Prostate Cancer Shots: The company reported the importance of precision medicine and prognostic tests that can help to determine cancer & enables personalized treatment paths. The company highlights the ability of genetic…

Read more

Viewpoints_Denis Corin

PharmaShots Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US Department of Defense and Veterans Affairs. Shots: BioMed has signed a 5-year agreement to commercially serve the US Department of Veterans Affairs (VA) and Department of Defense…

Read more

Viewpoints_Dr. Todd D. Cohen

PharmaShots Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment

In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the ability of a biomarker test to predict which men with aggressive prostate cancer will benefit from advanced hormonal therapy and which men with lower-risk prostate cancer can safely avoid such treatments.…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]